SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/16/22 Nano Mobile Healthcare, Inc. 8-K:5 1/18/22 10:189K SEC Filing Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 29K 5: R1 Cover HTML 48K 8: XML IDEA XML File -- Filing Summary XML 11K 6: XML XBRL Instance -- f2svnth8k051622_htm XML 15K 7: EXCEL IDEA Workbook of Financial Reports XLSX 6K 3: EX-101.LAB XBRL Labels -- vnth-20220114_lab XML 96K 4: EX-101.PRE XBRL Presentations -- vnth-20220114_pre XML 64K 2: EX-101.SCH XBRL Schema -- vnth-20220114 XSD 12K 9: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 10: ZIP XBRL Zipped Folder -- 0001903596-22-000298-xbrl Zip 11K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i January 18, 2022
i NANO MOBILE HEALTHCARE, INC.
(Exact Name of Registrant as Specified in its Charter)
i Nevada (State or other jurisdiction of incorporation) |
i 000-55155 (Commission File Number) |
i 98-0659770 (I.R.S. Employer Identification No.) |
i 370
Amapola Avenue i Suite 200-A
i Torrance,
i CA i 90501
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: i (424) i 358-1046
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i [X]
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which registered |
i Common Stock, par value of $0.00001 | i VNTH | OTCMKTS |
C:
SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.
On January 18, 2022, the Company appointed Mr. Frank I Igwealor as its President and CEO, effectively immediately. The Company believes that Mr. Igwealor’s vast experience would help to find a suitable merger for the Company to capitalize on emerging opportunities in the Web3, Gaming, Crypto and Metaverse industries. The Company also believes that bringing Mr. Igwealor back to actively manage the Company will provide it with the vision and grit to achieve its objectives.
C:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NANO MOBILE HEALTHCARE, INC.
Date: May 16, 2022 | By: /s/ Frank I Igwealor | |
Name: | Frank I Igwealor, JD, MBA, CPA, CMA, CFM, MSRM, ESQ. | |
Title: | Interim Chairman |
C:
C:
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 5/17/22 | 8-K, C-AR | ||
Filed as of: | 5/16/22 | 8-K | ||
For Period end: | 1/18/22 | 8-K | ||
List all Filings |